Wegovy weight loss at 3 months: a realistic timeline

Step 1, Month one: starting low and letting your body adjust

Treatment begins at 0.25 mg once weekly. This is a tolerability step; the dose exists to ease your system into the medicine rather than to produce immediate weight reduction. Most people notice some reduction in appetite within the first couple of weeks, though the scale may not move dramatically yet.

Nausea is common in this opening phase, the most frequently reported side effect across the STEP 1 trial published in the New England Journal of Medicine. Eating smaller portions, avoiding very fatty or spicy food, and staying well hydrated all help. For most people, the discomfort settles within a week or two of each dose step.

Your pen is a pre-filled, once-weekly device that arrives via DPD in plain, unmarked packaging, the same plain box whether it's your first order or your fifth. Storing it in the fridge door is all that's needed between doses.

Weight loss in month one is typically modest: somewhere in the 1–3% range for many people, and if you want to understand what Wegovy weight loss typically looks like after two months, that context helps set realistic expectations for what comes next. The medicine is doing groundwork rather than producing its ceiling effect.

Step 2, Month two: the dose increases and appetite drops more noticeably

At the four-week mark the prescriber moves the dose to 0.5 mg, and again around week eight to 1.0 mg if tolerated. Each increase tends to bring a short wave of gastrointestinal symptoms, milder than the first, usually, and shorter-lived. The experience of being two months in is often described as the point where appetite suppression becomes genuinely noticeable day to day.

Cumulative weight loss by the end of month two tends to sit in the 4–7% range for people who have been consistent with a reduced-calorie diet alongside treatment. Protein intake and staying active matter here: semaglutide reduces appetite across the board, so making sure the food you do eat is nutrient-dense helps preserve muscle mass.

This is also the phase where some people worry they are not losing fast enough. Progress at two months is not predictive of the full result, the trial data make clear that meaningful loss continues long after the initial weeks, because the maintenance dose (2.4 mg) hasn't been reached yet.

Step 3, Month three: assessing where you are and what comes next

By week 12, most people are somewhere between 1.0 mg and 1.7 mg weekly. A handful reach 2.4 mg ahead of schedule if tolerance has been excellent; others remain at 1.0 mg a little longer. The titration schedule is set by the prescriber, not self-directed.

At this point the data from the STEP 1 trial suggest average losses in the range of 6–9% of starting weight, though the range is wide. People with higher starting BMIs sometimes see larger absolute losses; those who have already lost weight before starting may see a slower pace. Crucially, weight loss in the trial continued accumulating up to around week 60, three months is genuinely early in the full trajectory.

If you are curious about how the picture continues to develop, the six-month Wegovy weight-loss page covers what happens once the maintenance dose is established. Cost is a practical factor to plan for too, the Wegovy pricing page sets out what private treatment involves transparently, without hidden fees.

The question of progress at three months also overlaps with NICE's guidance: NICE TA875 recommends reviewing treatment if less than 5% weight loss has been achieved after six months at the highest tolerated dose. Three months is too early to apply that threshold, but it is a useful marker to discuss with your prescriber.

When three months shows less progress than expected

Some people reach the three-month mark and feel their weight loss has been slower than they hoped. This is a common concern, and there are several straightforward reasons why it happens. The dose may not yet have reached a level where appetite suppression is strong enough to drive a significant deficit. Gastrointestinal side effects may have made consistent eating difficult. Or the lifestyle changes alongside treatment may need reviewing with a clinician.

The page on Wegovy and stalled weight loss at four months goes into more detail on the practical steps worth considering. Switching from Wegovy to a different treatment, or adjusting the dose, is a prescriber decision based on the full clinical picture, not something to self-manage. For more on how semaglutide works at a mechanistic level, that background can help explain why the timeline varies between individuals.

The right response to slow early progress is usually patience and a conversation with your prescriber, not stopping treatment. If you have questions specific to your situation, our support team is available seven days a week, and a prescriber review can be arranged through your consultation. Speak to our prescribers, that conversation is free and without obligation.